Rhumbline Advisers Raises Stock Position in XOMA Co. (NASDAQ:XOMA)

Rhumbline Advisers lifted its position in shares of XOMA Co. (NASDAQ:XOMA) by 18.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,065 shares of the biotechnology company’s stock after acquiring an additional 1,699 shares during the quarter. Rhumbline Advisers owned 0.09% of XOMA worth $291,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Geode Capital Management LLC boosted its position in XOMA by 0.6% during the third quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company’s stock worth $4,840,000 after purchasing an additional 1,138 shares in the last quarter. State Street Corp raised its stake in shares of XOMA by 1.2% during the 3rd quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock worth $3,783,000 after buying an additional 1,754 shares during the last quarter. Barclays PLC boosted its position in shares of XOMA by 300.7% in the 3rd quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock worth $298,000 after buying an additional 8,447 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its stake in XOMA by 95.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 795 shares during the last quarter. Institutional investors and hedge funds own 95.92% of the company’s stock.

Insiders Place Their Bets

In related news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the company’s stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $26.10, for a total transaction of $13,069,366.20. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. 7.20% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts have issued reports on XOMA shares. HC Wainwright cut their target price on shares of XOMA from $123.00 to $104.00 and set a “buy” rating for the company in a research report on Monday, February 3rd. StockNews.com downgraded XOMA from a “hold” rating to a “sell” rating in a research report on Tuesday, February 25th.

XOMA Trading Up 0.6 %

XOMA stock opened at $21.82 on Monday. The stock has a 50-day moving average price of $25.41 and a 200 day moving average price of $27.69. XOMA Co. has a 52 week low of $20.76 and a 52 week high of $35.00. The stock has a market cap of $257.11 million, a PE ratio of -6.27 and a beta of 1.00. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 1.28.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.